Macnealy Hoover Investment Management Inc. increased its position in Pfizer, Inc. (NYSE:PFE) by 1.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 39,232 shares of the biopharmaceutical company’s stock after buying an additional 450 shares during the period. Macnealy Hoover Investment Management Inc.’s holdings in Pfizer were worth $1,318,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Asset Planning Services Ltd. boosted its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. boosted its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. boosted its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new stake in Pfizer during the first quarter worth $121,000. Finally, Cascade Investment Advisors Inc. boosted its stake in Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares in the last quarter. 70.10% of the stock is owned by institutional investors and hedge funds.
Pfizer, Inc. (PFE) traded down 0.045% on Thursday, hitting $33.435. The stock had a trading volume of 6,058,145 shares. The company has a market capitalization of $199.53 billion, a PE ratio of 24.459 and a beta of 1.00. The company has a 50 day moving average of $33.44 and a 200 day moving average of $33.30. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.64 earnings per share. On average, equities analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.83%. Pfizer’s payout ratio is 94.12%.
TRADEMARK VIOLATION NOTICE: “Macnealy Hoover Investment Management Inc. Buys 450 Shares of Pfizer, Inc. (PFE)” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2800681/macnealy-hoover-investment-management-inc-buys-450-shares-of-pfizer-inc-pfe.html.
PFE has been the subject of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “neutral” rating and set a $35.00 price target (up from $34.00) on shares of Pfizer in a report on Thursday, April 13th. Sanford C. Bernstein reaffirmed a “buy” rating and set a $35.00 price target on shares of Pfizer in a report on Monday, April 24th. BMO Capital Markets reaffirmed a “hold” rating and set a $33.00 price target on shares of Pfizer in a report on Thursday, April 27th. Barclays PLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Finally, Citigroup Inc. cut Pfizer from a “neutral” rating to a “sell” rating and dropped their price target for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $37.77.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.